Contents
Immusoft is developing an approach to sustained delivery of protein therapeutics using a patient's own cells. The approach is called Immune System Programming (ISPTM). ISP entails collecting a type of the patient's immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.
Timeline
No Timeline data yet.
Further Resources
Title
Author
Link
Type
Date
No Further Resources data yet.
References
Company attributes
Industry
Location
B2X
Founder
Pitchbook URL
Legal Name
Immusoft Corporation
Number of Employees (Ranges)
11 – 50
Full Address
454 North 34th Street Seattle, WA 98103 United States
CIK Number
Investors
DUNS Number
831407775
Founded Date
January 1, 2009
Email Address
info@immusoft.com
Total Funding Amount (USD)
37,917,000
Latest Funding Round Date
September 2020
Latest Funding Type
Patents Assigned (Count)
3
Country
Other attributes
Company Operating Status
Active
